The search for a new Alzheimer's treatment just hit another setback

• An experimental drug to treat Alzheimer's disease just failed a late-stage trial.
• VTV Therapeutics, a small company in North Carolina, was developing an Alzheimer's drug azeliragon to inhibit the RAGE receptor, ideally to help people with mild Alzheimer's delay cognitive decline.
• Its phase 3 trial wrapped up in early 2018, but the treatment, when compared to placebo, "did not improve in cognitive or functional outcomes." The company is discontinuing its clinical trials.
• "We will continue to analyze the datasets and trends within subgroups from both Part A and Part B to determine if there are potential benefits or future uses and applications for azeliragon," VTV CEO Steve Holcombe said in a news release Monday.

NOW WATCH: A $700 billion investor dispels one of the market's most common myths - and explains what it means for your portfolio